Home Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
Article Open Access

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients

This article has been retracted. Retraction note.
  • Sahar K. Hegazy , Samar Tharwat and Ahmed H. Hassan EMAIL logo
Published/Copyright: August 9, 2023

Abstract

Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies combination against COVID-19. Standard antiviral therapy against COVID-19 includes remdesivir and favipiravir. The objectives were to compare progression and multi-organ function of hospitalized COVID-19 patients between these three antiviral groups. 265 COVID-19 hospitalized patients were included in this study and were divided into 3 groups (1:2:2), respectively, Group (A): casirivimab and imdevimab, group (B): remdesivir, and group (C): favipiravir. The design of the study is a single blind non-randomized controlled trial. This study is a phase IV clinical trial (post-marketing study). The duration of the study was about 6 months after receiving the ethical approval. Casirivimab and imdevimab achieved less case progression as presented by lower World Health Organization scale (P < 0.05 in comparing group A with B and C) and better multi-organ functions as presented by lower Sequential Organ Function Assessment score (P < 0.05 in comparing group A with B and C) than remdesivir and favipiravir. From all these results, it is concluded that Group A (casirivimab and imdevimab) produces better outcomes than B (remdesivir) and C (favipiravir) intervention groups.

1 Introduction

1.1 Coronavirus disease 2019 (COVID-19) overview and classification

COVID-19 is an infectious disease caused by sever acute respiratory syndrome-corona virus 2 (SARS CoV-2) that has affected a lot of human beings all over the world with high mortality rate [1]. COVID-19 infection has been classified [2] as:

Mild: Individuals who have any of the various signs and symptoms of COVID-19 without respiratory symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste, and smell) but not having dyspnea, shortness of breath, or abnormal chest imaging.

Moderate: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging, and who have an oxygen saturation (SpO2) ≥94% in room air at sea level.

Severe: Individuals suffer from lower respiratory disease with saturation pressure of oxygen (SpO2) <94% in room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, respiratory frequency >30 breaths/min, or lung infiltrates >50%.

Critical: Individuals have respiratory failure, septic shock, and/or multiple organ dysfunctions.

Covid-19 crisis causes a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged [3].

1.2 Standard and controversial antivirals used in treatment of COVID-19 (remdesivir and favipiravir)

Remdesivir has been approved by Food and Drug Administration (FDA) for treatment of mild, moderate, severe, and critical hospitalized COVID-19 patients [4]. Other drugs have shown controversial antiviral activity including favipiravir, hydroxychloroquine, ivermectin, nitazoxanide, and ribavirin. Favipiravir was selected from all other investigational antiviral agents, as it is the most investigational antiviral agent used for COVID-19 in Egypt.

Favipiravir has become a standard antiviral drug. Favipiravir is used for treatment of mild and moderate COVID-19 outpatients [5].

1.3 Advances in immunotherapy for treatment of COVID-19

Immunotherapy to target virus antigen has been developed [6]. Figure 1 shows two types of immunotherapies, active and passive immunotherapies. In active immunotherapy, body produces antibodies against virus as vaccination. Passive immunotherapy involves direct administration of antibodies to act specifically against virus or administration of product containing antibodies like plasma [6].

Figure 1 
                  Immunization approaches against COVID-19 [6].
Figure 1

Immunization approaches against COVID-19 [6].

There are three targets for these antibodies to work as antiviral including antibodies that prevent the virus entry, antibodies that inhibit the virus replication, and antibodies that stop the immune system response.

Table 1 includes various types of antibodies under investigation for treatment of COVID-19 and their targets [6].

Table 1

Antibody candidates against SARS-CoV-2 under investigation by pharmaceutical companies [6]

Antibody Mechanism Company Stage of study/identification method
Gimsilumab Anti GM-CSF monoclonal antibody Roivant Sciences In clinical stage for inflammation and rheumatic disease. Prioritized in clinical trial for SARS-CoV-2
Lenzilumab Humanigen Inc. Currently in clinical stage for leukemia and lymphoma
Canakinumab (Ilaris®) IL-1β inhibitor Novartis In clinical stage for several inflammatory diseases including arthritis, periodic fever, and lung cancer;Repurposed by Novartis for COVID-19
Secukinumab (Cosentyx®) IL-17 inhibitor Novartis In clinical stage for several autoimmune diseases including psoriasis; Repurposed by Novartis for COVID-19
TZLS-501 Fully human monoclonal antibody targeting the receptor of IL-6, it binds to both membrane-bound and soluble forms of IL-6R, and rapidly depletes the circulating levels of IL-6 in blood Tiziana Life Sciences and Novimmune Preclinical stage
ALT-100 Neutralizes circulating NAMPT Aqualung Therapeutics Corp. Preclinical stage
Pritumumab Fully human IgG antibody targeting vimentin Nascent Biotech Inc. Received FDA approval for several carcinoma; Research began for COVID-19
Leronlimab (PRO140) Antagonizes CCR5 on T-cells and prevents viral entry CytoDyn A 10-patient clinical study against COVID-19; Initially developed against HIV; in clinical trial for HIV and breast cancer
BDB-1 Anti C5a Beijing Defengrei Biotechnology Beijing Defengrei Biotechnology passes the phase II of clinical trial
IFX-1 InflaRx InflaRx received approval for starting the clinical trial in Netherlands
Antibody cocktail including REGN3048 and REGN3051 Fully human multivalent antibodies against the spike protein isolated from genetically modified mice or recovered COVID-19 patients Regeneron Phase 1 clinical trial for Middle East Respiratory Syndrome (MERS) completed last yearClinical trial for SARS-CoV

1.4 Casirivimab and imdevimab as antibodies cocktail against COVID-19

The point of research is antibodies cocktail including REGN3048 and REGN3051 that refers to two monoclonal antibodies REGN3048 (casirivimab), and REGN3051 (imdevimab) which prevent viral entry into human cells through the angiotensin-converting enzyme 2 receptor [7,8], and have shown an antiviral activity and need for further investigation to prove their benefit in COVID patients [9].

Previous study [9] that was conducted on REGN3048 and REGN3051 ((REGN-COV2 [casirivimab and imdevimab]) has mentioned that efficacy of both these antibodies cocktail is confirmed in COVID-19 outpatients’ treatment in both low (2.4 g of REGN-COV2), or high (8.0 g of REGN-COV2) dose when compared to placebo.

Efficacy is measured as virologic efficacy: Time-weighted change in viral load from baseline through day 7 (log10 scale) in patient, and clinical efficacy: Symptoms offset on day 7 and percentage of patients with one or more medically attended visits.

This previous study [9] proved that efficacy is more obvious in seronegative outpatients (whose immune response is not effective yet to produce antibodies against virus) and with high baseline viral load outpatients.

Now, data [10] are available for these new antibodies’ combination. The US FDA has allowed an Emergency Use Authorization (EUA) for this combination in the post-exposure prophylaxis and treatment of mild and moderate COVID-19 outpatients with positive PCR results of direct SARS-CoV-2 viral testing, and patients at high risk for progression to severe COVID-19 requiring hospitalization or causing death.

In contrast, REGN3048 and REGN3051 are still not authorized for use in patients who require oxygen therapy due to COVID-19, who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity, and who are hospitalized due to COVID-19 [10].

Now, casirivimab and imdevimab are investigational antibodies, serious and unexpected adverse effects can occur that were not previously reported with their use [10]

These antibodies combination follows linear pharmacokinetics after its single intravenous doses with half-life of about 25–37 days for both antibodies. Regarding elimination, this combination is not metabolized by liver cytochrome enzymes, and not excreted by kidneys [10].

Limitations of previous study include not using many of the clinically relevant outcomes like mortality rate, study performed on non-hospitalized patients only and not including hospitalized patients (trial is done only on outpatients and not inpatients), and not studying the long-term effects of antiviral efficacy in lowering viral load on inflammatory markers.

This research is an extension of a published research article [11].

2 Aim of the study

The objectives of this study were to compare case progression as presented by World Health Organization (WHO) scale and multi-organ function as presented by Sequential Organ Function Assessment (SOFA) score in hospitalized COVID-19 patients between the three antiviral groups.

3 Patients and population

265 COVID-19 hospitalized patients were included in this study and were divided into 3 groups (1:2:2): group A received Antibodies cocktail (casirivimab and imdevimab), group B received remdesivir, and group C received favipiravir [11].

Population in this study were patients hospitalized in isolation hospital Mansoura university.

A computer file containing a written informed consent from included patients was provided. Paper was not a tool for providing agreement by patients or their relatives to avoid transmission of infection.

3.1 Inclusion criteria

weight not less than 40 kg, PCR- confirmed patients to be positive before inclusion, age more than 12 years old, and moderate, sever, or critical COVID-19 disease as defined by WHO [11].

3.2 Exclusion criteria

Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltamivir, acyclovir, ribavirin, lopinavir/ritonavir, sofosbuvir, daclatasvir, simeprevir, azithromycin), prior use of standard antiviral therapy (remdesivir or favipiravir), history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies, and patients expected to die within 48 h [11].

3.3 Interventions

Population, that were included in this study, were assigned into three groups with 1:2:2 ratios to receive either antibodies combination, remdesivir, or favipiravir as shown in Figures 2 and 3.

Figure 2 
                  Assignment of the included COVID cases to their groups.
Figure 2

Assignment of the included COVID cases to their groups.

Figure 3 
                  Frequency of interventions in included patients.
Figure 3

Frequency of interventions in included patients.

Group A patients received REGN3048 and REGN3051(antibodies cocktail, casirivimab and imdevimab) in low-dose regimen of 1.2 g (1,200 mg of combined antibodies) diluted in 250 mL 0.9% sodium chloride solution as single IV infusion over 30–60 min.

Group B patients received remdesivir:

Day 1 (loading dose): 200 mg (two 100 mg vials) diluted in 500 mL 0.9% sodium chloride solution as infused IV over 60 min.

Days 2–5 or days 2–10 (maintenance dose): 100 mg (one 100 mg vial) in 250 mL 0.9% sodium chloride solution as infused IV over 30 min.

Group C patients received favipiravir:

Day 1 (loading dose): 1,600 mg (8 tablets) or 1,800 mg (9 tablets) orally or in Ryle tube/12 h

Days 2–5 or days 2–10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube/12 h

Patients received standard care guided by Egyptian COVID-19 treatment guidelines.

  1. Consent to participate: The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments; All subjects provided informed consent to participate in the study; Written informed consent was obtained from all participants; Written informed consent was obtained from parent/guardian of each participant under 18 years of age; The authors declare that they followed their institutions’ protocols to access the patient’s data and that was done with the unique purpose of the scientific investigation and scientific disclosure.

4 Materials and methods

Design of the study was a single blind non-randomized controlled trial. This study was phase IV clinical trial (post-marketing study) to evaluate efficacy of new pharmaceutical products. The duration of the study was about 6 months. Longitudinal model and correlation structure had been used in this research [11].

We used PubMed search tool to find clinical studies that were performed to test the efficacy of the developed immunotherapy in the treatment of COVID-19 with about 4,000 results with focusing on antibodies developed as antiviral against COVID-19 obtaining only 70 results from which REGN-COV2, a neutralizing antibody cocktail is selected with its only one clinical study up to now (REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19) which is published in New England Journal of Medicine on January 21, 2021.

Another resource, used to obtain data, was fact sheet for health care providers- EUA OF casirivimab and imdevimab which provides clinical data about the use of these antibodies cocktail [11]. Endnote citation software was used for citation of references.

Informed consent was obtained from each patient included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a prior approval by the institution’s human research committee.

The research protocol was approved by IRB, faculty of medicine, Mansoura University, MS21.11.1737, Research ethics committee, faculty of medicine, Tanta University, 35039/11/21, and Research ethics committee, ministry of health, Egypt, 10-2022/18.

Registry name and registration number: Clinicaltrials.gov, NCT05502081.

5 Outcomes

Clinical outcomes measured before and during intervention include: COVID19 WHO disease progression score [12] from day 0 to day 28, and SOFA score [13] on day 0, 3, 7, 14, and 28.

In addition to clinical outcomes measured after intervention, patients’ characteristics (age and gender) were recorded at the time of admission.

Duration of research was about 6 months from November 2021 to April 2022 [11].

6 Statistical analysis and sample size

Categorical variables were presented as proportion and percent. Continuous variables were presented as mean (standard deviation) for parametric data or as a median (25th–75th percentile) for non-parametric data [11].

Regarding baseline characteristics, Kruskal–Wallis or ANOVA test (depending on the type of data and the continuous data distribution [normal or not]) was used to compare these characteristics between the study groups. We reported the P-value for our statistical tests with the level of statistical significance as P-value ≤0.05 [11].

In case of existing differences in some baseline characteristics, logistic regression would be performed. This allowed studying the effect of these variables on the primary outcomes of the study to exclude the effect of these confounding variables and to ensure that the effect on the outcomes is due to interventions [11].

Regarding the outcomes, we compared WHO scale, and SOFA score using the Kruskal–Walli’s test, with the reported P-value [11].

6.1 Sample size

A total sample size of 246 patients would achieve at least 80% power to detect a risk difference of 0.2 (20%) in the WHO scale and SOFA score with a significance level (α) of 0.05 and 95% confidence level using the ANOVA or Kruskal–Wallis test of independent proportion in G*Power software. To compensate for the estimated loss-to-follow-up and increase the study power, we increased the sample size in both remdesivir and favipiravir groups to be 106 patients compared to 53 patients in antibodies cocktail group as antibodies cocktail product is available for only about 50 COVID-19 patients. In addition, the ratio (1:2:2) was the closest to reality according to the number of patients who received each drug [11].

The admission rate at Mansoura University – Isolation Hospital was 250 cases per month on average; our needed sample was about 250 cases.

7 Results

After statistical analysis using SPSS software, all continuous data showed no normal distribution. So Kruskal–Wallis test was used to compare abnormally distributed continuous, categorical, and nominal variables between the three groups [11].

7.1 Regarding baseline characteristics

Table 2 shows the significance of difference between the three groups and also includes a pairwise comparison between every two groups in baseline characteristics if they show a statistically significant difference between the three groups Figures S1–S9 represent distributions and frequencies of baseline characteristics between the three groups [11].

Table 2

Significance of differences in baseline characteristics between the three groups

7.1.1 Age

There is a statistically significant difference between A–C and B–C and a statistically non-significant difference between A–B [11].

7.1.2 Gender

There is a statistically significant difference between B–C and a statistically non-significant difference between A–B and A–C [11].

7.1.3 Number of comorbidities

There is a statistically significant difference between B–C and a statistically non-significant difference between A–B and A–C [11].

7.1.4 Method of diagnosis

There is a statistically non-significant difference between the three groups [11].

7.1.5 Severity of COVID-19

There is a statistically significant difference between A–B and A–C and a statistically non-significant difference between C-B. There are statistically significantly less severe cases in group A than in groups B and C [11].

7.1.6 Number of symptoms

There is a statistically significant difference between A–B and A–C and a statistically non-significant difference between C–B [11].

7.1.7 WHO clinical progression scale

There is a statistically significant difference between A–B and A–C and a statistically non-significant difference between C–B. WHO scale is statistically significantly lower in group A than groups B and C.

7.1.8 Multi-organ functions assessment

There is a statistically significant difference between the three groups in SOFA score.

7.2 Regression analysis

Regression analysis was performed to explore the effect of baseline characteristics (that show a statistically significant difference between the three groups) on the outcomes of the study and the possibility of existence of confounding variables as shown in Table 3 [11].

Table 3

Best regression model for studying effects of confounding variables on WHO scale score

Unstandardized coefficients Standardized coefficients t P-value
β Std. error β Std. error
(Constant) 0.806 1.297 0.621 0.535
Age 0.003 0.001 0.098 0.053 1.835 0.78
Gender 0.029 0.044 0.038 0.058 0.652 0.56
Number of co-morbidities –0.002 0.015 –0.007 0.048 –0.144 0.978
Severity of COVID –0.004 0.036 –0.007 0.059 –0.123 0.154
WHO clinical progression score 0.024 0.084 0.021 0.071 0.288 0.812
Number of symptoms 0.029 0.033 0.049 0.057 0.854 0.47
SOFA(1) 0.012 0.018 0.050 0.077 0.650 0.412

*P-value less than 0.05 is considered a statistically significant difference (1) Sequential Organ Function Assessment.

7.3 Regarding outcomes of the study after intervention in the three groups

Table 4 shows the significance of difference between the three groups and also includes a pairwise comparison between every two groups in clinical outcomes if they show a statistically significant difference between the three groups. Figures S10–S22 in the Supporting Information show the distributions and frequencies of these outcomes across the three groups [11].

Table 4

Significance of differences in outcomes between the three groups

7.3.1 Effect on score of multi-organ functions

There is a statistically significant difference in SOFA score on day 3 between the three groups and on days 7 and 14 between A–B and A–C and there are no other statistically significant differences between the groups were observed.

7.3.2 Effect on WHO scale for COVID cases

There is a statistically significant difference in WHO scale on days 3 and 7 between A–B and A–C and on day 14 between A–B only.

For more statistical analysis that is performed on the clinical data of this study, this is a link to a SPSS output file that contains all the statistical analysis of the study. An excel data sheet and a SPSS data file containing all clinical data of the cases of the three groups can be found in the below link in addition to an excel data sheet for included and excluded cases with date [11]: [deleted due to the policy violation].

8 Discussion

This study compared casirivimab and imdevimab with remdesivir and favipiravir for use in COVID-19 hospitalized patients. There are no similar treatment comparison or related studies to be compared with this research for similarity and differences [11].

8.1 Regarding baseline characteristics

The patients’ ages in groups A and B were statistically significantly lower than that in group C. There were statistically significantly more females in group B than group C. The number of co-morbidities is statistically significantly more in group C than Group B. There are statistically significantly less severe cases in group A than groups B and C. There are statistically significantly a smaller number of symptoms in group A than groups B and C. The who scale is statistically significantly lower in group A than groups B and C. Also, SOFA score is higher in group C than groups A and B and in group B than group A. So, A > B > C in multi-organ functions (multi-organ functions were better in A than in B and in B than in C)

8.2 Regression analysis

After statistical analysis of baseline characteristics of the cases in the three groups and finding that statistically significant differences in some baseline characteristics existed between the three groups, differences existed between age, gender, number of symptoms, number of co-morbidities, severity of COVID, WHO clinical progression scale, and SOFA score [11].

So, it was necessary to exclude the effect of these variables on the outcomes of the study which was represented by WHO scale score.

For this reason, regression analysis was performed to explore the effects of these variables on the WHO scale score.

After regression analysis, it was found that all baseline characteristics that differed between the three groups had no effect on the study outcome [11].

8.3 Regarding outcomes of the study after intervention in the three groups

SOFA score on day 3 was statistically significantly higher in group C than groups A and B and in group B than group A, SOFA score on days 7 and 14 was statistically significantly lower in group A than groups B and C. From these results, it is concluded that the best multi-organ functions are A > B > C with group A having the best multi-organ functions (lowest SOFA score).

Group A has a statistically significantly lower WHO progression scale than Groups B and C on days 3 and 7 and a statistically significantly lower WHO progression scale than Group B on day 14 that proves that less progression of the cases in Group A (lower WHO scale) than Groups B and C.

Limitations of this study includes non-randomization of antiviral drugs among included patients, non-blinding of interventions to investigators, applicable only on hospitalized COVID-19 patients (not including outpatients), and the differences in some baseline characteristics between the groups [11].

8.3.1 Generalizations of this study

This study can be generalized on hospitalized COVID-19 patients only and not involve all COVID-19 patients [11].

9 Conclusion

Casirivimab and imdevimab achieve less case progression as presented by lower WHO scale and better multi-organ functions as presented by lower SOFA score than remdesivir and favipiravir groups.

From the results, it is observed that Group A (casirivimab and imdevimab) provides better outcomes than groups B (remdesivir) and C (favipiravir).

This research is a long study as posted in the preprint because it contains several outcomes to investigate efficacy and safety of the casirivimab and imdevimab and the other two antiviral agents, so this research is divided into five parts (all parts of the same introduction, methods, patients, and interventions) and will be published in five stages as described in the study protocol due to size limitation in journal publishing. So, this part of the research is an extension of a recently published research paper that was prepared by the same authors. Clinical study to compare the efficacy and safety of casirivimab and imdevimab, remdesivir, and favipiravir in hospitalized COVID-19 patients that has been cited in the manuscript (reference no: 11) is available in the following links:https://doi.org/10.1016/j.jcvp.2023.100151, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169321/, https://www.sciencedirect.com/science/article/pii/S2667038023000182?via%3Dihub Preprints for this study are available at two websites. Clinical study to evaluate the possible efficacy and safety of antibodies combination (casirivimab and imdevimab) vs standard antiviral therapy as antiviral agent against coronavirus-2 infection in hospitalized COVID-19 patients is available in the following links: https://www.medrxiv.org/content/10.1101/2022.08.20.22279020v2.full.pdf, https://www.researchsquare.com/article/rs-1991618/v2. For more statistical analysis that is performed on clinical data of this study, below is the link to an SPSS output file that contains all the statistical analysis of the study. An excel data sheet and an SPSS data file containing all clinical data of the cases of the three groups can be found in this link in addition to an excel data sheet for included and excluded cases with date: [deleted due to the policy violation].


tel: +20-155465810

Acknowledgement

The authors thank study participants for their involvement in the study.

  1. Funding information: No funding sources.

  2. Author contributions: Ahmed H. Hassan: conceptualization, data curation, methodology, roles/writing – original draft, writing – review and editing; Sahar K. Hegazy: conceptualization, project administration, supervision; and Samar T. Radwan: supervision.

  3. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose.

  4. Data availability statement: The datasets generated and/or analyzed during the current study are available in the Clinicaltrials.gov repository, https://clinicaltrials.gov/ct2/show/NCT05502081.

References

[1] Okonji EF, Okonji OC, Mukumbang FC. Understanding varying COVID-19 mortality rates reported in Africa compared to Europe, America and Asia. Trop Med Int Health. 2021;26(7):716–9. https://onlinelibrary.wiley.com/, 10.1111/tmi.13575.Search in Google Scholar PubMed PubMed Central

[2] National Institute of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [updated September 29, 2021]. https://www.covid19treatmentguidelines.nih.gov/.Search in Google Scholar

[3] Umakanthan S, Chattu VK, Ranade AV, Das D, Basavarajegowda A, Bukelo M. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. AIMS Public Health. 2021;8(1):137–53. http://www.aimspress.com/article/, 10.3934/publichealth.2021011.Search in Google Scholar PubMed PubMed Central

[4] Aleem A, Kothadia JP. Remdesivir StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC. PMID: 3308-5408. https://www.ncbi.nlm.nih.gov/books/NBK563261/.Search in Google Scholar

[5] De Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, et al. COVID-19 therapy: What weapons do we bring into battle? Bioorg Med Chem. 2020;28(23):115–757. 10.1016/j.bmc.2020.115757%222020.115757.Search in Google Scholar

[6] Owji H, Negahdaripour M, Hajighahramani N. Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol. 2020;88:106–924. 10.1016/j.bmc.2020.115757%222020.115757.Search in Google Scholar

[7] Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–8. 10.1126/science.abd0831.Search in Google Scholar PubMed PubMed Central

[8] Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–4. 10.1126/science.abd0827.Search in Google Scholar PubMed PubMed Central

[9] Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;384(3):238–51. https://www.nejm.org/, 10.1056/NEJMoa2035002.Search in Google Scholar PubMed PubMed Central

[10] Food and Drug Administration. Emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab): Food and Drug Administration (FDA); 2021 [updated 16/9/2021]. first: [fact sheet for health care providers]. https://www.fda.gov/media/145611/download.Search in Google Scholar

[11] Hegazy SK, Tharwat S, Hassan AH. Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipiravir in hospitalized COVID-19 patients. J Clin Virol Plus. 2023;3(2):100151. 10.1016/j.jcvp.2023.100151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169321/ https://www.sciencedirect.com/science/article/pii/S2667038023000182?via%3Dihub.Search in Google Scholar PubMed PubMed Central

[12] Plaçais L, Richier Q, Noël N, Lacombe K, Mariette X, Hermine O. Immune interventions in COVID-19: A matter of time? Mucosal Immunol. 2022;15:198–210.10.1038/s41385-021-00464-wSearch in Google Scholar PubMed PubMed Central

[13] Yang Z, Hu Q, Huang F, Xiong S, Sun Y. The prognostic value of the SOFA score in patients with COVID-19: A retrospective, observational study. Medicine (Baltimore). 2021;100:e26900.10.1097/MD.0000000000026900Search in Google Scholar PubMed PubMed Central

Received: 2023-03-11
Revised: 2023-06-20
Accepted: 2023-07-08
Published Online: 2023-08-09

© 2023 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Research Articles
  2. Exosomes derived from mesenchymal stem cells overexpressing miR-210 inhibits neuronal inflammation and contribute to neurite outgrowth through modulating microglia polarization
  3. Current situation of acute ST-segment elevation myocardial infarction in a county hospital chest pain center during an epidemic of novel coronavirus pneumonia
  4. circ-IARS depletion inhibits the progression of non-small-cell lung cancer by circ-IARS/miR-1252-5p/HDGF ceRNA pathway
  5. circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma
  6. WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
  7. Up-regulation of collagen type V alpha 2 (COL5A2) promotes malignant phenotypes in gastric cancer cell via inducing epithelial–mesenchymal transition (EMT)
  8. Inhibition of TERC inhibits neural apoptosis and inflammation in spinal cord injury through Akt activation and p-38 inhibition via the miR-34a-5p/XBP-1 axis
  9. 3D-printed polyether-ether-ketone/n-TiO2 composite enhances the cytocompatibility and osteogenic differentiation of MC3T3-E1 cells by downregulating miR-154-5p
  10. Propofol-mediated circ_0000735 downregulation restrains tumor growth by decreasing integrin-β1 expression in non-small cell lung cancer
  11. PVT1/miR-16/CCND1 axis regulates gastric cancer progression
  12. Silencing of circ_002136 sensitizes gastric cancer to paclitaxel by targeting the miR-16-5p/HMGA1 axis
  13. Short-term outcomes after simultaneous gastrectomy plus cholecystectomy in gastric cancer: A pooling up analysis
  14. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways
  15. Molecular mechanism by which the Notch signaling pathway regulates autophagy in a rat model of pulmonary fibrosis in pigeon breeder’s lung
  16. lncRNA TPT1-AS1 promotes cell migration and invasion in esophageal squamous-cell carcinomas by regulating the miR-26a/HMGA1 axis
  17. SIRT1/APE1 promotes the viability of gastric cancer cells by inhibiting p53 to suppress ferroptosis
  18. Glycoprotein non-metastatic melanoma B interacts with epidermal growth factor receptor to regulate neural stem cell survival and differentiation
  19. Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
  20. Association of osteoporosis and skeletal muscle loss with serum type I collagen carboxyl-terminal peptide β glypeptide: A cross-sectional study in elder Chinese population
  21. circ_0000376 knockdown suppresses non-small cell lung cancer cell tumor properties by the miR-545-3p/PDPK1 pathway
  22. Delivery in a vertical birth chair supported by freedom of movement during labor: A randomized control trial
  23. UBE2J1 knockdown promotes cell apoptosis in endometrial cancer via regulating PI3K/AKT and MDM2/p53 signaling
  24. Metabolic resuscitation therapy in critically ill patients with sepsis and septic shock: A pilot prospective randomized controlled trial
  25. Lycopene ameliorates locomotor activity and urinary frequency induced by pelvic venous congestion in rats
  26. UHRF1-induced connexin26 methylation is involved in hearing damage triggered by intermittent hypoxia in neonatal rats
  27. LINC00511 promotes melanoma progression by targeting miR-610/NUCB2
  28. Ultra-high-performance liquid chromatography-tandem mass spectrometry analysis of serum metabolomic characteristics in people with different vitamin D levels
  29. Role of Jumonji domain-containing protein D3 and its inhibitor GSK-J4 in Hashimoto’s thyroiditis
  30. circ_0014736 induces GPR4 to regulate the biological behaviors of human placental trophoblast cells through miR-942-5p in preeclampsia
  31. Monitoring of sirolimus in the whole blood samples from pediatric patients with lymphatic anomalies
  32. Effects of osteogenic growth peptide C-terminal pentapeptide and its analogue on bone remodeling in an osteoporosis rat model
  33. A novel autophagy-related long non-coding RNAs signature predicting progression-free interval and I-131 therapy benefits in papillary thyroid carcinoma
  34. WGCNA-based identification of potential targets and pathways in response to treatment in locally advanced breast cancer patients
  35. Radiomics model using preoperative computed tomography angiography images to differentiate new from old emboli of acute lower limb arterial embolism
  36. Dysregulated lncRNAs are involved in the progress of myocardial infarction by constructing regulatory networks
  37. Single-arm trial to evaluate the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy
  38. Genetic polymorphisms of MRPS30-DT and NINJ2 may influence lung cancer risk
  39. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
  40. Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma
  41. Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis
  42. CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p
  43. Exosomal miR-93-5p regulated the progression of osteoarthritis by targeting ADAMTS9
  44. Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells
  45. HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway
  46. The association between sleep duration, quality, and nonalcoholic fatty liver disease: A cross-sectional study
  47. Myostatin silencing inhibits podocyte apoptosis in membranous nephropathy through Smad3/PKA/NOX4 signaling pathway
  48. A novel long noncoding RNA AC125257.1 facilitates colorectal cancer progression by targeting miR-133a-3p/CASC5 axis
  49. Impact of omicron wave and associated control measures in Shanghai on health management and psychosocial well-being of patients with chronic conditions
  50. Clinicopathological characteristics and prognosis of young patients aged ≤45 years old with non-small cell lung cancer
  51. TMT-based comprehensive proteomic profiling identifies serum prognostic signatures of acute myeloid leukemia
  52. The dose limits of teeth protection for patients with nasopharyngeal carcinoma undergoing radiotherapy based on the early oral health-related quality of life
  53. miR-30b-5p targeting GRIN2A inhibits hippocampal damage in epilepsy
  54. Long non-coding RNA AL137789.1 promoted malignant biological behaviors and immune escape of pancreatic carcinoma cells
  55. IRF6 and FGF1 polymorphisms in non-syndromic cleft lip with or without cleft palate in the Polish population
  56. Comprehensive analysis of the role of SFXN family in breast cancer
  57. Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy
  58. Silencing of long noncoding RNA MIAT inhibits the viability and proliferation of breast cancer cells by promoting miR-378a-5p expression
  59. AG1024, an IGF-1 receptor inhibitor, ameliorates renal injury in rats with diabetic nephropathy via the SOCS/JAK2/STAT pathway
  60. Downregulation of KIAA1199 alleviated the activation, proliferation, and migration of hepatic stellate cells by the inhibition of epithelial–mesenchymal transition
  61. Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment
  62. Inhibition of glycolysis represses the growth and alleviates the endoplasmic reticulum stress of breast cancer cells by regulating TMTC3
  63. The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma
  64. Tectorigenin alleviates the apoptosis and inflammation in spinal cord injury cell model through inhibiting insulin-like growth factor-binding protein 6
  65. Ultrasound examination supporting CT or MRI in the evaluation of cervical lymphadenopathy in patients with irradiation-treated head and neck cancer
  66. F-box and WD repeat domain containing 7 inhibits the activation of hepatic stellate cells by degrading delta-like ligand 1 to block Notch signaling pathway
  67. Knockdown of circ_0005615 enhances the radiosensitivity of colorectal cancer by regulating the miR-665/NOTCH1 axis
  68. Long noncoding RNA Mhrt alleviates angiotensin II-induced cardiac hypertrophy phenotypes by mediating the miR-765/Wnt family member 7B pathway
  69. Effect of miR-499-5p/SOX6 axis on atrial fibrosis in rats with atrial fibrillation
  70. Cholesterol induces inflammation and reduces glucose utilization
  71. circ_0004904 regulates the trophoblast cell in preeclampsia via miR-19b-3p/ARRDC3 axis
  72. NECAB3 promotes the migration and invasion of liver cancer cells through HIF-1α/RIT1 signaling pathway
  73. The poor performance of cardiovascular risk scores in identifying patients with idiopathic inflammatory myopathies at high cardiovascular risk
  74. miR-2053 inhibits the growth of ovarian cancer cells by downregulating SOX4
  75. Nucleophosmin 1 associating with engulfment and cell motility protein 1 regulates hepatocellular carcinoma cell chemotaxis and metastasis
  76. α-Hederin regulates macrophage polarization to relieve sepsis-induced lung and liver injuries in mice
  77. Changes of microbiota level in urinary tract infections: A meta-analysis
  78. Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
  79. Falls during oxaliplatin-based chemotherapy for gastrointestinal malignancies – (lessons learned from) a prospective study
  80. Outcomes of low-risk birth care during the Covid-19 pandemic: A cohort study from a tertiary care center in Lithuania
  81. Vitamin D protects intestines from liver cirrhosis-induced inflammation and oxidative stress by inhibiting the TLR4/MyD88/NF-κB signaling pathway
  82. Integrated transcriptome analysis identifies APPL1/RPS6KB2/GALK1 as immune-related metastasis factors in breast cancer
  83. Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme
  84. Circular RNA Circ_0038467 promotes the maturation of miRNA-203 to increase lipopolysaccharide-induced apoptosis of chondrocytes
  85. An economic evaluation of fine-needle cytology as the primary diagnostic tool in the diagnosis of lymphadenopathy
  86. Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
  87. Network pharmacology combined with molecular docking and experimental validation to reveal the pharmacological mechanism of naringin against renal fibrosis
  88. PTPN12 down-regulated by miR-146b-3p gene affects the malignant progression of laryngeal squamous cell carcinoma
  89. miR-141-3p accelerates ovarian cancer progression and promotes M2-like macrophage polarization by targeting the Keap1-Nrf2 pathway
  90. lncRNA OIP5-AS1 attenuates the osteoarthritis progression in IL-1β-stimulated chondrocytes
  91. Overexpression of LINC00607 inhibits cell growth and aggressiveness by regulating the miR-1289/EFNA5 axis in non-small-cell lung cancer
  92. Subjective well-being in informal caregivers during the COVID-19 pandemic
  93. Nrf2 protects against myocardial ischemia-reperfusion injury in diabetic rats by inhibiting Drp1-mediated mitochondrial fission
  94. Unfolded protein response inhibits KAT2B/MLKL-mediated necroptosis of hepatocytes by promoting BMI1 level to ubiquitinate KAT2B
  95. Bladder cancer screening: The new selection and prediction model
  96. circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
  97. Prone position effect in intensive care patients with SARS-COV-2 pneumonia
  98. Clinical observation on the efficacy of Tongdu Tuina manipulation in the treatment of primary enuresis in children
  99. Dihydroartemisinin ameliorates cerebral I/R injury in rats via regulating VWF and autophagy-mediated SIRT1/FOXO1 pathway
  100. Knockdown of circ_0113656 assuages oxidized low-density lipoprotein-induced vascular smooth muscle cell injury through the miR-188-3p/IGF2 pathway
  101. Low Ang-(1–7) and high des-Arg9 bradykinin serum levels are correlated with cardiovascular risk factors in patients with COVID-19
  102. Effect of maternal age and body mass index on induction of labor with oral misoprostol for premature rupture of membrane at term: A retrospective cross-sectional study
  103. Potential protective effects of Huanglian Jiedu Decoction against COVID-19-associated acute kidney injury: A network-based pharmacological and molecular docking study
  104. Clinical significance of serum MBD3 detection in girls with central precocious puberty
  105. Clinical features of varicella-zoster virus caused neurological diseases detected by metagenomic next-generation sequencing
  106. Collagen treatment of complex anorectal fistula: 3 years follow-up
  107. LncRNA CASC15 inhibition relieves renal fibrosis in diabetic nephropathy through down-regulating SP-A by sponging to miR-424
  108. Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line Helicobacter pylori eradication regimen – An open-label, randomized trial
  109. SMOC2 plays a role in heart failure via regulating TGF-β1/Smad3 pathway-mediated autophagy
  110. A prospective cohort study of the impact of chronic disease on fall injuries in middle-aged and older adults
  111. circRNA THBS1 silencing inhibits the malignant biological behavior of cervical cancer cells via the regulation of miR-543/HMGB2 axis
  112. hsa_circ_0000285 sponging miR-582-3p promotes neuroblastoma progression by regulating the Wnt/β-catenin signaling pathway
  113. Long non-coding RNA GNAS-AS1 knockdown inhibits proliferation and epithelial–mesenchymal transition of lung adenocarcinoma cells via the microRNA-433-3p/Rab3A axis
  114. lncRNA UCA1 regulates miR-132/Lrrfip1 axis to promote vascular smooth muscle cell proliferation
  115. Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia
  116. Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene
  117. Anti-inflammatory effect of ApoE23 on Salmonella typhimurium-induced sepsis in mice
  118. Analysis of somatic mutations and key driving factors of cervical cancer progression
  119. Hsa_circ_0028007 regulates the progression of nasopharyngeal carcinoma through the miR-1179/SQLE axis
  120. Variations in sexual function after laparoendoscopic single-site hysterectomy in women with benign gynecologic diseases
  121. Effects of pharmacological delay with roxadustat on multi-territory perforator flap survival in rats
  122. Analysis of heroin effects on calcium channels in rat cardiomyocytes based on transcriptomics and metabolomics
  123. Risk factors of recurrent bacterial vaginosis among women of reproductive age: A cross-sectional study
  124. Alkbh5 plays indispensable roles in maintaining self-renewal of hematopoietic stem cells
  125. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
  126. Correlation between microvessel maturity and ISUP grades assessed using contrast-enhanced transrectal ultrasonography in prostate cancer
  127. The protective effect of caffeic acid phenethyl ester in the nephrotoxicity induced by α-cypermethrin
  128. Norepinephrine alleviates cyclosporin A-induced nephrotoxicity by enhancing the expression of SFRP1
  129. Effect of RUNX1/FOXP3 axis on apoptosis of T and B lymphocytes and immunosuppression in sepsis
  130. The function of Foxp1 represses β-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity
  131. Risk model and validation of carbapenem-resistant Klebsiella pneumoniae infection in patients with cerebrovascular disease in the ICU
  132. Calycosin protects against chronic prostatitis in rats via inhibition of the p38MAPK/NF-κB pathway
  133. Pan-cancer analysis of the PDE4DIP gene with potential prognostic and immunotherapeutic values in multiple cancers including acute myeloid leukemia
  134. The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
  135. Circ-UBR4 regulates the proliferation, migration, inflammation, and apoptosis in ox-LDL-induced vascular smooth muscle cells via miR-515-5p/IGF2 axis
  136. Clinical characteristics of current COVID-19 rehabilitation outpatients in China
  137. Luteolin alleviates ulcerative colitis in rats via regulating immune response, oxidative stress, and metabolic profiling
  138. miR-199a-5p inhibits aortic valve calcification by targeting ATF6 and GRP78 in valve interstitial cells
  139. The application of iliac fascia space block combined with esketamine intravenous general anesthesia in PFNA surgery of the elderly: A prospective, single-center, controlled trial
  140. Elevated blood acetoacetate levels reduce major adverse cardiac and cerebrovascular events risk in acute myocardial infarction
  141. The effects of progesterone on the healing of obstetric anal sphincter damage in female rats
  142. Identification of cuproptosis-related genes for predicting the development of prostate cancer
  143. Lumican silencing ameliorates β-glycerophosphate-mediated vascular smooth muscle cell calcification by attenuating the inhibition of APOB on KIF2C activity
  144. Targeting PTBP1 blocks glutamine metabolism to improve the cisplatin sensitivity of hepatocarcinoma cells through modulating the mRNA stability of glutaminase
  145. A single center prospective study: Influences of different hip flexion angles on the measurement of lumbar spine bone mineral density by dual energy X-ray absorptiometry
  146. Clinical analysis of AN69ST membrane continuous venous hemofiltration in the treatment of severe sepsis
  147. Antibiotics therapy combined with probiotics administered intravaginally for the treatment of bacterial vaginosis: A systematic review and meta-analysis
  148. Construction of a ceRNA network to reveal a vascular invasion associated prognostic model in hepatocellular carcinoma
  149. A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
  150. A prognostic signature based on seven T-cell-related cell clustering genes in bladder urothelial carcinoma
  151. Pepsin concentration in oral lavage fluid of rabbit reflux model constructed by dilating the lower esophageal sphincter
  152. The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC
  153. Tanshinone IIA attenuates valvular interstitial cells’ calcification induced by oxidized low density lipoprotein via reducing endoplasmic reticulum stress
  154. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
  155. Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes
  156. Trial protocol: Feasibility of neuromodulation with connectivity-guided intermittent theta-burst stimulation for improving cognition in multiple sclerosis
  157. LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer
  158. Factors associated with gastrointestinal dysmotility in critically ill patients
  159. Mechanisms by which spinal cord stimulation intervenes in atrial fibrillation: The involvement of the endothelin-1 and nerve growth factor/p75NTR pathways
  160. Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics
  161. Silencing USP19 alleviates cigarette smoke extract-induced mitochondrial dysfunction in BEAS-2B cells by targeting FUNDC1
  162. Menstrual irregularities associated with COVID-19 vaccines among women in Saudi Arabia: A survey during 2022
  163. Ferroptosis involves in Schwann cell death in diabetic peripheral neuropathy
  164. The effect of AQP4 on tau protein aggregation in neurodegeneration and persistent neuroinflammation after cerebral microinfarcts
  165. Activation of UBEC2 by transcription factor MYBL2 affects DNA damage and promotes gastric cancer progression and cisplatin resistance
  166. Analysis of clinical characteristics in proximal and distal reflux monitoring among patients with gastroesophageal reflux disease
  167. Exosomal circ-0020887 and circ-0009590 as novel biomarkers for the diagnosis and prediction of short-term adverse cardiovascular outcomes in STEMI patients
  168. Upregulated microRNA-429 confers endometrial stromal cell dysfunction by targeting HIF1AN and regulating the HIF1A/VEGF pathway
  169. Bibliometrics and knowledge map analysis of ultrasound-guided regional anesthesia
  170. Knockdown of NUPR1 inhibits angiogenesis in lung cancer through IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways
  171. D-dimer trends predict COVID-19 patient’s prognosis: A retrospective chart review study
  172. WTAP affects intracranial aneurysm progression by regulating m6A methylation modification
  173. Using of endoscopic polypectomy in patients with diagnosed malignant colorectal polyp – The cross-sectional clinical study
  174. Anti-S100A4 antibody administration alleviates bronchial epithelial–mesenchymal transition in asthmatic mice
  175. Prognostic evaluation of system immune-inflammatory index and prognostic nutritional index in double expressor diffuse large B-cell lymphoma
  176. Prevalence and antibiogram of bacteria causing urinary tract infection among patients with chronic kidney disease
  177. Reactive oxygen species within the vaginal space: An additional promoter of cervical intraepithelial neoplasia and uterine cervical cancer development?
  178. Identification of disulfidptosis-related genes and immune infiltration in lower-grade glioma
  179. A new technique for uterine-preserving pelvic organ prolapse surgery: Laparoscopic rectus abdominis hysteropexy for uterine prolapse by comparing with traditional techniques
  180. Self-isolation of an Italian long-term care facility during COVID-19 pandemic: A comparison study on care-related infectious episodes
  181. A comparative study on the overlapping effects of clinically applicable therapeutic interventions in patients with central nervous system damage
  182. Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome: Long-term follow-up
  183. The diagnostic accuracy of touch imprint cytology for sentinel lymph node metastases of breast cancer: An up-to-date meta-analysis of 4,073 patients
  184. Mortality associated with Sjögren’s syndrome in the United States in the 1999–2020 period: A multiple cause-of-death study
  185. CircMMP11 as a prognostic biomarker mediates miR-361-3p/HMGB1 axis to accelerate malignant progression of hepatocellular carcinoma
  186. Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations
  187. KMT2A maintains stemness of gastric cancer cells through regulating Wnt/β-catenin signaling-activated transcriptional factor KLF11
  188. Evaluation of placental oxygenation by near-infrared spectroscopy in relation to ultrasound maturation grade in physiological term pregnancies
  189. The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
  190. Construction of immunogenic cell death-related molecular subtypes and prognostic signature in colorectal cancer
  191. Long-term prognostic value of high-sensitivity cardiac troponin-I in patients with idiopathic dilated cardiomyopathy
  192. Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients
  193. Integrative bioinformatics analysis reveals STAT2 as a novel biomarker of inflammation-related cardiac dysfunction in atrial fibrillation
  194. Adipose-derived stem cells repair radiation-induced chronic lung injury via inhibiting TGF-β1/Smad 3 signaling pathway
  195. Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort
  196. lncRNA LENGA sponges miR-378 to promote myocardial fibrosis in atrial fibrillation
  197. Diagnostic value of urinary Tamm-Horsfall protein and 24 h urine osmolality for recurrent calcium oxalate stones of the upper urinary tract: Cross-sectional study
  198. The value of color Doppler ultrasonography combined with serum tumor markers in differential diagnosis of gastric stromal tumor and gastric cancer
  199. The spike protein of SARS-CoV-2 induces inflammation and EMT of lung epithelial cells and fibroblasts through the upregulation of GADD45A
  200. Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
  201. MiR-1278 targets CALD1 and suppresses the progression of gastric cancer via the MAPK pathway
  202. Metabolomic analysis of serum short-chain fatty acid concentrations in a mouse of MPTP-induced Parkinson’s disease after dietary supplementation with branched-chain amino acids
  203. Cimifugin inhibits adipogenesis and TNF-α-induced insulin resistance in 3T3-L1 cells
  204. Predictors of gastrointestinal complaints in patients on metformin therapy
  205. Prescribing patterns in patients with chronic obstructive pulmonary disease and atrial fibrillation
  206. A retrospective analysis of the effect of latent tuberculosis infection on clinical pregnancy outcomes of in vitro fertilization–fresh embryo transferred in infertile women
  207. Appropriateness and clinical outcomes of short sustained low-efficiency dialysis: A national experience
  208. miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD
  209. Clinical features and management of lymphoepithelial cyst
  210. Serum VEGF, high-sensitivity CRP, and cystatin-C assist in the diagnosis of type 2 diabetic retinopathy complicated with hyperuricemia
  211. ENPP1 ameliorates vascular calcification via inhibiting the osteogenic transformation of VSMCs and generating PPi
  212. Significance of monitoring the levels of thyroid hormone antibodies and glucose and lipid metabolism antibodies in patients suffer from type 2 diabetes
  213. The causal relationship between immune cells and different kidney diseases: A Mendelian randomization study
  214. Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units
  215. Identification of diagnostic immune-related gene biomarkers for predicting heart failure after acute myocardial infarction
  216. Long-term administration of probiotics prevents gastrointestinal mucosal barrier dysfunction in septic mice partly by upregulating the 5-HT degradation pathway
  217. miR-192 inhibits the activation of hepatic stellate cells by targeting Rictor
  218. Diagnostic and prognostic value of MR-pro ADM, procalcitonin, and copeptin in sepsis
  219. Review Articles
  220. Prenatal diagnosis of fetal defects and its implications on the delivery mode
  221. Electromagnetic fields exposure on fetal and childhood abnormalities: Systematic review and meta-analysis
  222. Characteristics of antibiotic resistance mechanisms and genes of Klebsiella pneumoniae
  223. Saddle pulmonary embolism in the setting of COVID-19 infection: A systematic review of case reports and case series
  224. Vitamin C and epigenetics: A short physiological overview
  225. Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
  226. Aspirin versus LMWH for VTE prophylaxis after orthopedic surgery
  227. Mechanism of rhubarb in the treatment of hyperlipidemia: A recent review
  228. Surgical management and outcomes of traumatic global brachial plexus injury: A concise review and our center approach
  229. The progress of autoimmune hepatitis research and future challenges
  230. METTL16 in human diseases: What should we do next?
  231. New insights into the prevention of ureteral stents encrustation
  232. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature
  233. Case Reports
  234. Mycobacterium xenopi infection of the kidney and lymph nodes: A case report
  235. Genetic mutation of SLC6A20 (c.1072T > C) in a family with nephrolithiasis: A case report
  236. Chronic hepatitis B complicated with secondary hemochromatosis was cured clinically: A case report
  237. Liver abscess complicated with multiple organ invasive infection caused by hematogenous disseminated hypervirulent Klebsiella pneumoniae: A case report
  238. Urokinase-based lock solutions for catheter salvage: A case of an upcoming kidney transplant recipient
  239. Two case reports of maturity-onset diabetes of the young type 3 caused by the hepatocyte nuclear factor 1α gene mutation
  240. Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
  241. Does total hip arthroplasty result in intercostal nerve injury? A case report and literature review
  242. Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi – Case report and literature review
  243. Synchronous triple primary gastrointestinal malignant tumors treated with laparoscopic surgery: A case report
  244. CT-guided percutaneous microwave ablation combined with bone cement injection for the treatment of transverse metastases: A case report
  245. Malignant hyperthermia: Report on a successful rescue of a case with the highest temperature of 44.2°C
  246. Anesthetic management of fetal pulmonary valvuloplasty: A case report
  247. Rapid Communication
  248. Impact of COVID-19 lockdown on glycemic levels during pregnancy: A retrospective analysis
  249. Erratum
  250. Erratum to “Inhibition of miR-21 improves pulmonary vascular responses in bronchopulmonary dysplasia by targeting the DDAH1/ADMA/NO pathway”
  251. Erratum to: “Fer exacerbates renal fibrosis and can be targeted by miR-29c-3p”
  252. Retraction
  253. Retraction of “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
  254. Retraction of “circ_0062491 alleviates periodontitis via the miR-142-5p/IGF1 axis”
  255. Retraction of “miR-223-3p alleviates TGF-β-induced epithelial-mesenchymal transition and extracellular matrix deposition by targeting SP3 in endometrial epithelial cells”
  256. Retraction of “SLCO4A1-AS1 mediates pancreatic cancer development via miR-4673/KIF21B axis”
  257. Retraction of “circRNA_0001679/miR-338-3p/DUSP16 axis aggravates acute lung injury”
  258. Retraction of “lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells”
  259. Special issue Linking Pathobiological Mechanisms to Clinical Application for cardiovascular diseases
  260. Effect of cardiac rehabilitation therapy on depressed patients with cardiac insufficiency after cardiac surgery
  261. Special issue The evolving saga of RNAs from bench to bedside - Part I
  262. FBLIM1 mRNA is a novel prognostic biomarker and is associated with immune infiltrates in glioma
  263. Special Issue Computational Intelligence Methodologies Meets Recurrent Cancers - Part III
  264. Development of a machine learning-based signature utilizing inflammatory response genes for predicting prognosis and immune microenvironment in ovarian cancer
Downloaded on 7.5.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2023-0768/html
Scroll to top button